UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
KIORA PHARMACEUTICALS, INC. |
(Name of Issuer) |
|
COMMON STOCK, PAR VALUE $0.01 PER SHARE |
(Title of Class of Securities) |
49721T101 |
(CUSIP Number) |
December 31, 2023 |
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
|
¨ |
Rule 13d-1(b) |
|
x |
Rule 13d-1(c) |
|
¨ |
Rule 13d-1(d) |
* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Page 1 of 12 Pages)
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 2 of 12 |
1 |
NAMES OF REPORTING PERSONS
Lincoln Park Capital Fund, LLC |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
OO |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, the reporting person
has rights, under the shares of Series F Convertible Preferred Stock of the Issuer (the “Series F”) and under five
warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock which, except for the contractual caps in the Series
F and warrants on the amount of outstanding shares of the Issuer’s Common Stock that the reporting person may own, when combined
with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%.
Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock beneficially owned by the reporting person was
768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on
its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents Reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting
person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer’s
Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s
Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted
Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9,
2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575 shares,
which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as
of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and
the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed
with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 3 of 12 |
1 |
NAMES OF REPORTING PERSONS
Lincoln Park Capital, LLC |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
OO |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has
rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock
which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s Common Stock
that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership
cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock
beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of
November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As
of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number
of shares of the Issuer’s Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding
shares of the Issuer’s Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and
900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%.
Thus, as of February 9, 2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575
shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the
7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities
Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024,
as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 4 of 12 |
1 |
NAMES OF REPORTING PERSONS
Rockledge Capital Corporation |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Texas |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
CO |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has
rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock
which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s Common Stock
that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership
cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock
beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of
November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As
of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number
of shares of the Issuer’s Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding
shares of the Issuer’s Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and
900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%.
Thus, as of February 9, 2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575
shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the
7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities
Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024,
as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 5 of 12 |
1 |
NAMES OF REPORTING PERSONS
Joshua B. Scheinfeld |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
IN |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has
rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock
which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s Common Stock
that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership
cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock
beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of
November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As
of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number
of shares of the Issuer’s Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding
shares of the Issuer’s Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and
900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%.
Thus, as of February 9, 2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575
shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the
7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities
Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024,
as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 6 of 12 |
1 |
NAMES OF REPORTING PERSONS
Alex Noah Investors, Inc. |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
CO |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has
rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock
which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s Common Stock
that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership
cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock
beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of
November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As of February 9, 2024, reporting
person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number of shares of the Issuer’s
Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s
Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and 900,000 shares of restricted
Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%. Thus, as of February 9,
2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575 shares,
which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the 7,689,240 shares of Common Stock outstanding as
of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023, and
the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024, as provided by the Issuer on a Form 8-K filed
with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 7 of 12 |
1 |
NAMES OF REPORTING PERSONS
Jonathan I. Cope |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH: |
5 |
SOLE VOTING POWER
0 |
6 |
SHARED VOTING POWER
768,155(1)/2,346,575(2) |
7 |
SOLE DISPOSITIVE POWER
0 |
8 |
SHARED DISPOSITIVE POWER
768,155(1)/2,346,575(2) |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
768,155(1)/2,346,575(2) |
10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%(3)/9.99%(4) |
12 |
TYPE OF REPORTING PERSON
IN |
1. Represents reporting person’s beneficial ownership of Common
Stock as of December 31, 2023.
2. Represents reporting person’s beneficial ownership of Common
Stock as of February 9, 2024.
3. Represents reporting person’s percent of beneficial ownership
of Common Stock outstanding as of December 31, 2023. As of December 31, 2023, reporting person has
rights, under the shares of Series F and under five warrants, to acquire an aggregate number of shares of the Issuer’s Common Stock
which, except for the contractual caps in the Series F and warrants on the amount of outstanding shares of the Issuer’s Common Stock
that the reporting person may own, when combined with the 130,139 shares of Common Stock owned, would exceed such a cap. The ownership
cap in each of the Series F and warrants is 9.99%. Thus, as of December 31, 2023, the number of shares of the Issuer’s Common Stock
beneficially owned by the reporting person was 768,155 shares, which is 9.99% of the 7,689,240 shares of Common Stock outstanding as of
November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities Exchange Commission on November 9, 2023.
4. Represents reporting
person’s percent of beneficial ownership of Common Stock outstanding as of February 9, 2024. As
of February 9, 2024, reporting person has rights, under the shares of Series F and under seven warrants, to acquire an aggregate number
of shares of the Issuer’s Common Stock which, except for the contractual caps in the Series F and warrants on the amount of outstanding
shares of the Issuer’s Common Stock that the reporting person may own, when combined with the 17,500 shares of Common Stock and
900,000 shares of restricted Common Stock owned, would exceed such a cap. The ownership cap in each of the Series F and warrants is 9.99%.
Thus, as of February 9, 2024, the number of shares of the Issuer’s Common Stock that the reporting person may own was 2,346,575
shares, which is 9.99% of the 23,489,240 shares outstanding, which was calculated by adding the
7,689,240 shares of Common Stock outstanding as of November 6, 2023, as provided by the Issuer on its Form 10-Q filed with the Securities
Exchange Commission on November 9, 2023, and the 15,800,000 shares of Common Stock issued in a private placement dated January 31, 2024,
as provided by the Issuer on a Form 8-K filed with the Securities Exchange Commission on February 1, 2024.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 8 of 12 |
Item 1. |
|
|
(a) |
Name of Issuer: |
|
|
|
|
|
Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”) |
|
|
|
|
(b) |
Address of Issuer’s Principal Executive Offices: |
|
|
|
|
|
332 Encinitas Blvd., Suite 102, Encinitas, CA 92024 |
Item 2. |
|
|
(a) |
Name of Person Filing: |
|
|
|
|
|
Lincoln Park Capital Fund, LLC (“LPC Fund”) |
|
|
Lincoln Park Capital, LLC (“LPC”) |
|
|
Rockledge Capital Corporation (“RCC”) |
|
|
Joshua B. Scheinfeld (“Mr. Scheinfeld”) |
|
|
Alex Noah Investors, Inc. (“Alex Noah”) |
|
|
Jonathan I. Cope (“Mr. Cope” and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the “Reporting Persons”) |
|
|
|
|
(b) |
Address of Principal Business Office, or if None, Residence: |
|
|
|
|
|
The address of the principal business office of each of the Reporting Persons is: |
|
|
440 North Wells, Suite 410 |
|
|
Chicago, Illinois 60654 |
|
|
|
|
(c) |
Citizenship: |
|
|
|
|
|
LPC Fund is an Illinois limited liability company |
|
|
LPC is an Illinois limited liability company |
|
|
RCC is a Texas corporation |
|
|
Mr. Scheinfeld is a United States citizen |
|
|
Alex Noah is an Illinois corporation |
|
|
Mr. Cope is a United States citizen |
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 9 of 12 |
|
|
|
|
(d) |
Title of Class of Securities: |
|
|
|
|
|
Common Stock, Par Value $0.01 Per Share (“Common Stock”) |
|
|
|
|
(e) |
CUSIP Number: |
|
|
|
|
|
49721T101 |
|
|
|
Item 3. |
|
If this statement is filed pursuant to §§240.13d-1(b), or
240.13d-2(b) or (c), check whether the person filing is a:
(a) |
¨ |
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). |
(b) |
¨ |
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). |
(c) |
¨ |
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). |
(d) |
¨ |
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
(e) |
¨ |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
(f) |
¨ |
An employee benefit plan or endowment fund in accordance with §240. 13d-1(b)(1)(ii)(F); |
(g) |
¨ |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
(h) |
¨ |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
(i) |
¨ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) |
¨ |
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); |
(k) |
¨ |
Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance
with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ______________________
Item 4. Ownership.
Reporting person | |
Amount
beneficially owned: | |
Percent
of class: | |
Sole
power to vote or direct the vote: | |
Shared
power to
vote or to direct the vote: | |
Sole
power to dispose or to direct the disposition of: | |
Shared
power to dispose or to direct the disposition of: |
Lincoln Park Capital Fund, LLC | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
Lincoln Park Capital, LLC | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
Rockledge Capital Corporation | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
Joshua B. Scheinfeld | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
Alex Noah Investors, Inc. | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
Jonathan I. Cope | |
768,155(1)/2,346,575(2) | |
9.99% | |
0 | |
768,155(1)/2,346,575(2) | |
0 | |
768,155(1)/2,346,575(2) |
1. As of December 31, 2023, LPC Fund owned the
following securities of the Issuer: (i) 130,139 shares of outstanding Common Stock; (ii) warrants to purchase 828,919 shares of Common
Stock currently exercisable at $0.5231 per share that expire on June 6, 2026, subject to a 9.99% beneficial ownership cap (the “Series
C Warrants”); (iii) warrants to purchase 828,919 shares of Common Stock currently exercisable at $0.5231 per share that expire
on June 6, 2024, subject to a 9.99% beneficial ownership cap, (the “Series D Warrants”); (iv) warrants to purchase
105,596 shares of Common Stock currently exercisable at $3.538 that expire on August 3, 2028, subject to a 9.99% beneficial ownership
cap, pursuant to a securities purchase agreement dated February 2, 2023 (the “2023 SPA Warrants”); (v) warrants to
purchase 121,875 shares of Common Stock currently exercisable at $5.97 per share that expire on November 22, 2024, subject to a 9.99%
beneficial ownership cap, pursuant to a private placement on or about November 22, 2022 (the “2022 PP Warrants”); (vi)
warrants to purchase 121,875 shares of Common Stock currently exercisable at $8.00 per share that expire on July 22, 2027, subject to
a 9.99% beneficial ownership cap (the “Additional Warrants”); and (vii) 570 shares of Series F that are convertible
into 381,780 shares of Common Stock, subject to a 9.99% beneficial ownership cap.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 10 of 12 |
Based on the information provided
on Issuer’s Form 10-Q, filed with the Securities Exchange Commission on November 9, 2023, there were 7,689,240 shares of Common
Stock Outstanding. Accordingly, as of December 31, 2023, LPC Fund directly beneficially owned an aggregate of 768,155 shares of Common
Stock, representing the 130,139 shares of Common Stock presently owned combined with number of shares of Common Stock that may be acquired
by LPC Fund as of December 31, 2023 under the above warrants and Series F without exceeding the 9.99% beneficial ownership limitation
on the exercise of the Warrants, or the 9.99% beneficial ownership limitation on the conversion of the Series F.
2. As of February 9, 2024, LPC Fund owned the
following securities of the Issuer: (i) 17,500 shares of outstanding Common Stock; (ii) warrants to purchase 818,236 shares of Common
Stock currently exercisable at a price of $0.6076 per share, which expires on the earlier date of: (a) February 5, 2029 and (b) 30 days
after the Company announces topline data from a Phase 2 clinical trial (ABACUS-2) of KIO-301 in retinitis pigmentosa and, following such
announcement, the daily volume weighted average price of the Issuer’s common stock equals or exceeds $1.1048 for 30 consecutive
trading days (pursuant to Issuer’s Form 8-K, filed with the Securities Exchange Commission on February 1, 2024); (iii) warrants
to purchase 818,236 shares of Common Stock currently exercisable at a price of $0.6076 per share, which expires on the earlier date of:
(a) February 5, 2029 and (b) 30 days after the Company announces topline data from a Phase 2 clinical trial of KIO-104 for treatment in
posterior non-infectious uveitis and, following such announcement, the daily volume weighted average price of the Issuer’s common
stock equals or exceeds $1.3810 for 30 consecutive trading days (pursuant to Issuer’s Form 8-K, filed with the Securities Exchange
Commission on February 1, 2024); (iv) Series C Warrants to purchase up to 828,919 shares of Common Stock; (v) Series D Warrants to purchase
578,919 shares of Common Stock; (vi) 2023 SPA Warrants to purchase up to 105,596 shares of Common Stock; (vii) 2022 PP Warrants to purchase
up to 121,875 shares of Common Stock; (viii) 750 shares of Series F that are convertible into 381,780 shares of Common Stock; (viii) Additional
Warrants to purchase up to 121,875 shares of Common stock; and (ix) 900,000 shares of restricted Common Stock
Pursuant to §240.13d-1,
which states that “any person, in determining the amount of outstanding securities of a class of equity securities, may rely upon
information set forth in the issuer’s most recent quarterly or annual report, and any current report subsequent thereto, filed with
the Commission pursuant to this Act, unless he knows or has reason to believe that information contained therein is inaccurate,”
the Reporting Persons are including updated information in connection with the Issuer’s Current Report on Form 8-K, filed with the
Securities and Exchange Commission on February 1, 2024 (the “Current Report”). Based on the information provided in the Issuer’s
Quarterly Report on Form 10-Q, filed with the Securities Exchange Commission on November 9, 2023, where the Issuer disclosed that there
were 7,689,240 shares of Common Stock outstanding, and in the Current Report, where 15,800,000 shares
of Common Stock were issued in a private placement on or about January 31, 2024, the total Common Stock outstanding was 23,489,240 shares.
Accordingly, as of February 9, 2024, LPC Fund directly beneficially owned an aggregate of 2,347,575 shares of Common Stock, representing
the 17,500 shares of Common Stock presently owned and the 900,000 shares of restricted Common Stock currently owned, combined with number
of shares of Common Stock that may be acquired by LPC Fund as of February 9, 2024 under the above warrants and Series F without exceeding
the 9.99% beneficial ownership limitation on the exercise of the warrants, or the 9.99% beneficial ownership limitation on the conversion
of the Series F.
LPC is the Managing Member
of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as
a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing,
Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the shares of Common Stock of the Issuer held directly
by LPC Fund.
Pursuant to Section 13(d)
of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner
of the shares of Common Stock of the Issuer beneficially owned directly by LPC Fund.
The foregoing should not be
construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another
Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership
of the shares of Common Stock of the Issuer held directly by LPC Fund.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 11 of 12 |
Item 5. |
Ownership of Five Percent or Less of a Class. |
If this statement is being
filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent
of the class of securities, check the following ¨.
Item 6. |
Ownership of More Than Five Percent on Behalf of Another Person. |
|
|
|
Not applicable. |
|
|
Item 7. |
Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
|
|
|
Not applicable. |
|
|
Item 8. |
Identification and Classification of Members of the Group. |
|
|
|
Not applicable. |
|
|
Item 9. |
Notice of Dissolution of Group. |
|
|
|
Not applicable. |
|
|
Item 10. |
Certifications. |
By signing below I certify
that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SCHEDULE 13G
CUSIP NO. 49721T101 |
Page 12 of 12 |
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2024
LINCOLN PARK CAPITAL FUND, LLC |
|
LINCOLN PARK CAPITAL, LLC |
|
|
|
BY: |
LINCOLN PARK CAPITAL, LLC |
|
BY: |
ROCKLEDGE CAPITAL CORPORATION |
|
|
|
BY: |
ROCKLEDGE CAPITAL CORPORATION |
|
|
|
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Joshua B. Scheinfeld |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Joshua B. Scheinfeld |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
LINCOLN PARK CAPITAL FUND, LLC |
|
LINCOLN PARK CAPITAL, LLC |
|
|
|
BY: |
LINCOLN PARK CAPITAL, LLC |
|
BY: |
ALEX NOAH INVESTORS, INC. |
|
|
|
BY: |
ALEX NOAH INVESTORS, INC. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Jonathan I. Cope |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Jonathan I. Cope |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
ROCKLEDGE CAPITAL CORPORATION |
|
ALEX NOAH INVESTORS, INC. |
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
JOSHUA B. SCHEINFELD |
|
JONATHAN I. COPE |
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
LIST OF EXHIBITS
EXHIBIT 99.1
Joint Filing Agreement
The undersigned hereby agree
that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule
13G, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible
for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason
to believe that such information is inaccurate.
In accordance with Rule 13d-1(k)(1)
promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other
on behalf of each of them of such Schedule 13G with respect to the Common Stock of the Issuer, beneficially owned by each of them. This
Joint Filing Agreement shall be included as an exhibit to such Schedule 13G.
[Signature Page Follows]
IN WITNESS WHEREOF, the undersigned hereby execute
this Agreement as of February 14, 2023.
LINCOLN PARK CAPITAL FUND, LLC |
|
LINCOLN PARK CAPITAL, LLC |
|
|
|
BY: |
LINCOLN PARK CAPITAL, LLC |
|
BY: |
ROCKLEDGE CAPITAL CORPORATION |
|
|
|
BY: |
ROCKLEDGE CAPITAL CORPORATION |
|
|
|
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Joshua B. Scheinfeld |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Joshua B. Scheinfeld |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
LINCOLN PARK CAPITAL FUND, LLC |
|
LINCOLN PARK CAPITAL, LLC |
|
|
|
BY: |
LINCOLN PARK CAPITAL, LLC |
|
BY: |
ALEX NOAH INVESTORS, INC. |
|
|
|
BY: |
ALEX NOAH INVESTORS, INC. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Jonathan I. Cope |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Jonathan I. Cope |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
ROCKLEDGE CAPITAL CORPORATION |
|
ALEX NOAH INVESTORS, INC. |
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
|
|
|
JOSHUA B. SCHEINFELD |
|
JONATHAN I. COPE |
|
|
|
|
|
|
By: |
/s/ Joshua B. Scheinfeld |
|
By: |
/s/ Jonathan I. Cope |
|
Name: |
Joshua B. Scheinfeld |
|
|
Name: |
Jonathan I. Cope |
|
Title: |
President |
|
|
Title: |
President |
Kiora Pharmaceuticals (NASDAQ:KPRX)
過去 株価チャート
から 11 2024 まで 12 2024
Kiora Pharmaceuticals (NASDAQ:KPRX)
過去 株価チャート
から 12 2023 まで 12 2024